ANXIN

Anxin Biopharmaceutical is a clinical-stage biotechnology company based in Beijing, China, specializing in the development and industrialization of recombinant human proteins. The company's primary focus is the production of recombinant human serum albumin (rHSA), designed as a safer, animal-free alternative to plasma-derived albumin for treating conditions such as hypoproteinemia and liver cirrhosis. Anxin utilizes advanced yeast-based expression systems to achieve high-purity protein production at scale. Beyond its lead albumin program, the company is exploring other recombinant therapeutic proteins and vaccines. Anxin aims to address the chronic shortage of blood-derived products in the Chinese market through innovative biomanufacturing technologies.